Patient Care Editorial Staff

Articles

Icotrokinra Shows Promise for Moderate-to-Severe Plaque Psoriasis in Phase 3 Trials

March 08, 2025

Icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which is implicated in multiple inflammatory conditions including plaque psoriasis.

Real-World Evidence Reveals Key Insights on Hidradenitis Suppurativa

March 07, 2025

Two posters at AAD 2025 highlighted different challenges of managing patients with HS.

Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial

March 07, 2025

The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.

AAD 2025: Clear Skin in Half of Patients Who Received Monthly Maintenance Injection of Ebglyss for AD

March 07, 2025

The findings from the long-term extension ADjoin study will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.

AAD 2025: Atopic Dermatitis Preview

March 07, 2025

Preview the posters and abstracts covering atopic dermatitis advances from Arcutis, Incyte, Lilly and Sanofi/Regeneron.

FDA Accepts Depemokimab BLA for Asthma and Chronic Rhinosinusitis with Nasal Polyps

March 06, 2025

The FDA set the Prescription Drug User Fee Act (PDUFA) date for December 16, 2025.

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

March 06, 2025

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

FDA Approves Neffy 1 mg Epinephrine Nasal Spray, Only Needle-Free Treatment for Patients Weighing Less Than 30 kg

March 06, 2025

The FDA approval of neffy 1 mg follows the earlier approval of the 5 mg version in August 2024.

Measles Outbreak Explained: Disease History, Vaccine Breakthrough and 2025 Resurgence

February 27, 2025

The 2025 measles outbreak in Texas has reignited discussion surrounding vaccine-preventable diseases and the importance of maintaining high immunization rates.

New neffy (epinephrine nasal spray) Data To Be Shared in 9 Presentations at 2025 AAAAI

February 26, 2025

Data on the epinephrine nasal spray will include findings from an efficacy study comparing anaphylaxis symptoms during oral food challenge, according to ARS.